# Enhancing the Natriuretic Peptide System in HFpEF

> **NCT05279742** · PHASE1,PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Horng Chen** · enrollment: 60 (estimated)

## Conditions studied

- Heart Failure With Preserved Ejection Fraction
- Chronic Kidney Diseases

## Interventions

- **DRUG:** MANP
- **DRUG:** Sacubitril/Valsartan
- **DRUG:** Oral Placebo
- **DRUG:** Injection Placebo

## Key facts

- **NCT ID:** NCT05279742
- **Lead sponsor:** Horng Chen
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2022-11-04
- **Primary completion:** 2027-04
- **Final completion:** 2027-04
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2025-10-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05279742

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05279742, "Enhancing the Natriuretic Peptide System in HFpEF". Retrieved via AI Analytics 2026-07-03 from https://api.ai-analytics.org/clinical/NCT05279742. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*